RU2005105693A - Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний - Google Patents
Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний Download PDFInfo
- Publication number
- RU2005105693A RU2005105693A RU2005105693/15A RU2005105693A RU2005105693A RU 2005105693 A RU2005105693 A RU 2005105693A RU 2005105693/15 A RU2005105693/15 A RU 2005105693/15A RU 2005105693 A RU2005105693 A RU 2005105693A RU 2005105693 A RU2005105693 A RU 2005105693A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- alkylphosphocholines
- unbranched
- branched
- general formula
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 229940041181 antineoplastic drug Drugs 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- -1 cyano, hydroxyl Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 230000008054 signal transmission Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39961502P | 2002-07-30 | 2002-07-30 | |
| US60/399,615 | 2002-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005105693A true RU2005105693A (ru) | 2005-07-10 |
Family
ID=31495746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005105693/15A RU2005105693A (ru) | 2002-07-30 | 2003-07-29 | Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний |
Country Status (26)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2469727C2 (ru) * | 2005-12-19 | 2012-12-20 | Этерна Центарис ГмбХ | Способ лечения или профилактики заболеваний и/или патофизиологических состояний, вызванных микроорганизмами, посредством производных алкилфосфолипидов |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383605B2 (en) | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
| UA82322C2 (uk) | 2002-07-30 | 2008-04-10 | Центаріс Гмбх | Застосування алкілфосфохолінів в комбінації з протипухлинними лікарськими засобами |
| DE10324911B4 (de) | 2003-05-30 | 2005-08-18 | Siemens Ag | Röntgenvorrichtung mit partiellem digitalem Detektor und Verfahren zum Betrieb einer solchen |
| WO2006081452A2 (en) * | 2005-01-28 | 2006-08-03 | Robert Birch | Co-administration of perifosine with chemotherapeutics |
| US20070167408A1 (en) * | 2005-12-19 | 2007-07-19 | Zentaris Gmbh | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof |
| EP1800684A1 (en) * | 2005-12-20 | 2007-06-27 | Zentaris GmbH | Novel alkyl phospholipid derivatives and uses thereof |
| US8703179B2 (en) | 2006-05-11 | 2014-04-22 | Kimberly-Clark Worldwide, Inc. | Mucosal formulation |
| CN103479604B (zh) * | 2007-07-30 | 2016-08-10 | 阿迪生物科学公司 | 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法 |
| AU2009324464B2 (en) * | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8383607B2 (en) | 2010-03-31 | 2013-02-26 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2086026T3 (es) * | 1991-07-04 | 1996-06-16 | Asta Medica Ag | Farmaco con efecto antineoplasico que contiene como sustancia activa (2-(n-metil-piperidino)-etil)-fosfato de octadecilo y procedimiento para su preparacion. |
| US5942639A (en) * | 1991-07-04 | 1999-08-24 | Asta Medica Aktiengesellschaft | Process for the preparation of alkylphosphocholines and the production thereof in pure form |
| US6172050B1 (en) * | 1992-07-11 | 2001-01-09 | Asta Medica Aktiengesellschaft | Phospholipid derivatives |
| JP3079993B2 (ja) * | 1996-03-27 | 2000-08-21 | 日本電気株式会社 | 真空マイクロデバイスおよびその製造方法 |
| DE19650778C2 (de) * | 1996-12-06 | 2001-01-04 | Asta Medica Ag | Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie |
| CA2318260C (en) | 1998-01-22 | 2006-11-21 | Asta Medica Ag | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
| JP2002531534A (ja) * | 1998-12-04 | 2002-09-24 | マックス−デルブルック−セントラム フュール モレクラーレ メディツィン | タモキシフェン含有リポソーム系腫瘍治療剤 |
| US6583127B1 (en) | 1998-12-21 | 2003-06-24 | Inkeysa. Sa | Use of etherlysophospholipids as antiinflammatory agents |
| CN1551767A (zh) * | 2001-02-19 | 2004-12-01 | ��˹��ŵ�� | 癌症的治疗 |
| ATE450265T1 (de) * | 2001-03-23 | 2009-12-15 | Shire Canada Inc | Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält |
| WO2003005522A1 (es) | 2001-07-04 | 2003-01-16 | Acuna Arturo | Tapones para sellado de ductos para redes electricas, telefonicas y de fibra optica. |
| DE60210329T2 (de) * | 2002-01-02 | 2006-11-30 | Nerviano Medical Sciences S.R.L., Nerviano | Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren |
| UA82322C2 (uk) | 2002-07-30 | 2008-04-10 | Центаріс Гмбх | Застосування алкілфосфохолінів в комбінації з протипухлинними лікарськими засобами |
| WO2005000318A2 (en) * | 2003-06-23 | 2005-01-06 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| WO2006081452A2 (en) | 2005-01-28 | 2006-08-03 | Robert Birch | Co-administration of perifosine with chemotherapeutics |
| US20070167408A1 (en) | 2005-12-19 | 2007-07-19 | Zentaris Gmbh | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof |
| US8383607B2 (en) | 2010-03-31 | 2013-02-26 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
-
2003
- 2003-07-29 UA UAA200500510A patent/UA82322C2/uk unknown
- 2003-07-29 AR AR20030102710A patent/AR040717A1/es unknown
- 2003-07-29 CN CNB038181010A patent/CN1302780C/zh not_active Expired - Fee Related
- 2003-07-29 RU RU2005105693/15A patent/RU2005105693A/ru unknown
- 2003-07-29 MX MXPA05001203A patent/MXPA05001203A/es active IP Right Grant
- 2003-07-29 DK DK03766336.6T patent/DK1545553T3/da active
- 2003-07-29 SI SI200332027T patent/SI1545553T1/sl unknown
- 2003-07-29 CA CA2493023A patent/CA2493023C/en not_active Expired - Lifetime
- 2003-07-29 PT PT03766336T patent/PT1545553E/pt unknown
- 2003-07-29 HR HRP20050184AA patent/HRP20050184B1/hr not_active IP Right Cessation
- 2003-07-29 WO PCT/EP2003/008346 patent/WO2004012744A1/de not_active Ceased
- 2003-07-29 BR BR0313048-7A patent/BR0313048A/pt not_active IP Right Cessation
- 2003-07-29 AT AT03766336T patent/ATE516036T1/de active
- 2003-07-29 JP JP2004525354A patent/JP2005535688A/ja active Pending
- 2003-07-29 ES ES03766336T patent/ES2369535T3/es not_active Expired - Lifetime
- 2003-07-29 EP EP03766336A patent/EP1545553B1/de not_active Expired - Lifetime
- 2003-07-29 AU AU2003253350A patent/AU2003253350B2/en not_active Ceased
- 2003-07-29 KR KR1020057001510A patent/KR101066804B1/ko not_active Expired - Lifetime
- 2003-07-29 KR KR1020127034433A patent/KR20130016413A/ko not_active Ceased
- 2003-07-29 KR KR1020117017914A patent/KR20110102485A/ko not_active Ceased
- 2003-07-29 PL PL03375493A patent/PL375493A1/xx unknown
- 2003-07-29 TW TW092120705A patent/TWI332007B/zh not_active IP Right Cessation
- 2003-07-29 NZ NZ538428A patent/NZ538428A/en not_active IP Right Cessation
- 2003-07-29 EP EP10010451A patent/EP2301551A1/de not_active Withdrawn
- 2003-07-30 US US10/632,187 patent/US8389497B2/en not_active Expired - Fee Related
-
2005
- 2005-01-17 IL IL166329A patent/IL166329A/en not_active IP Right Cessation
- 2005-01-18 ZA ZA2005/00453A patent/ZA200500453B/en unknown
- 2005-02-25 NO NO20051040A patent/NO335196B1/no not_active IP Right Cessation
-
2008
- 2008-07-10 AU AU2008203060A patent/AU2008203060B2/en not_active Ceased
-
2010
- 2010-03-31 US US12/751,608 patent/US8507710B2/en not_active Expired - Fee Related
- 2010-03-31 US US12/751,454 patent/US8551977B2/en not_active Expired - Fee Related
-
2011
- 2011-09-30 CY CY20111100944T patent/CY1111902T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2469727C2 (ru) * | 2005-12-19 | 2012-12-20 | Этерна Центарис ГмбХ | Способ лечения или профилактики заболеваний и/или патофизиологических состояний, вызванных микроорганизмами, посредством производных алкилфосфолипидов |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102057751B1 (ko) | 테노포비르 전구약물 및 그의 약학적 용도 | |
| JP4982685B2 (ja) | ヒトがんを処置するための他の細胞毒剤又は細胞増殖抑制剤と組合わせたアリール尿素化合物 | |
| US8507710B2 (en) | Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals | |
| KR20210075992A (ko) | Sting 작동 화합물 | |
| RU2006122853A (ru) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы | |
| EA200401254A1 (ru) | Комбинированное применение противоопухолевого производного индолопирролокарбазола и другого противоопухолевого агента | |
| JP2007529421A5 (cg-RX-API-DMAC10.html) | ||
| AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
| CA2302568A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| RU2009114731A (ru) | Производное пиразолопиримидина | |
| RU2004135307A (ru) | Производное эпотилона для лечения гепатомы и других раковых заболеваний | |
| JP2016510723A (ja) | 転移抑制活性を有するリン含有糖アナログ複素環 | |
| EA200600377A1 (ru) | Новая композиция | |
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| AU2004222661B2 (en) | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments | |
| AU2011204918B2 (en) | Use of alkylphosphocholines in combination with antitumor medicaments | |
| RU2005128829A (ru) | Обладающие противоопухолевым действием 2-замещенные 18а-гомоэстра-1, 3, 5( 10 )-триен-3-илсульфаматы | |
| RU2023123879A (ru) | Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич | |
| BR0317244A (pt) | Derivados de piperazina contendo fósforo como antagonistas ccr1 | |
| KR20170091610A (ko) | 신규 peg 유도체 | |
| RU2004109224A (ru) | Соединения циклического амина | |
| CA2436332A1 (en) | Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals | |
| KR970703327A (ko) | 산 아미드 유도체 및 이들의 제조 방법(acid amide derivatives and process for the preparation thereof) | |
| TH2101001306A (th) | องค์ประกอบสำหรับการบำบัดรวม | |
| RU94038051A (ru) | Гетероциклические производные, способ их получения, фармацевтическая композиция и способ лечения |